zervimesine
Generic: CT1812·Code: CT1812
zervimesine: sourced relationships with 1 company · 1 clinical trial tracked.
zervimesine evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect zervimesine to CGTX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zervimesine → CGTX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| COGNITION THERAPEUTICS INC (CGTX) | Phase 2 |
Clinical Trial Registry Records (1)
A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).
Expanded Access8 sites · United StatesCognition Therapeutics
Frequently asked questions
Which companies have sourced relationships with zervimesine?
zervimesine has dated SEC/FDA relationship records for COGNITION THERAPEUTICS INC.
How many clinical trials involve zervimesine?
BioSniper tracks 1 clinical trial involving zervimesine.